Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 449

1.

Development of thyroid diseases in the treatment of chronic hepatitis C with alpha-interferon may be a good prognosticator in achieving a sustained virological response: a meta-analysis.

Tran HA, Malcolm Reeves GE, Gibson R, Attia JR.

J Gastroenterol Hepatol. 2009 Jul;24(7):1163-8. doi: 10.1111/j.1440-1746.2009.05874.x. Review.

PMID:
19682190
2.
3.

Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4.

El Makhzangy H, Esmat G, Said M, Elraziky M, Shouman S, Refai R, Rekacewicz C, Gad RR, Vignier N, Abdel-Hamid M, Zalata K, Bedossa P, Pol S, Fontanet A, Mohamed MK.

J Med Virol. 2009 Sep;81(9):1576-83. doi: 10.1002/jmv.21570.

PMID:
19626613
4.

Combination therapy of peginterferon and ribavirin for chronic hepatitis C patients with genotype 1b and low-virus load.

Arase Y, Suzuki F, Akuta N, Sezaki H, Suzuki Y, Kawamura Y, Kobayashi M, Hosaka T, Yatsuji H, Hirakawa M, Saito S, Ikeda K, Kobayashi M, Kumada H.

Intern Med. 2009;48(5):253-8. Epub 2009 Mar 2.

5.

Effects of combined interferon alpha and ribavirin therapy on thyroid functions in patients with chronic hepatitis C.

Nadeem A, Aslam M, Khan DA, Hussain T, Khan SA.

J Coll Physicians Surg Pak. 2009 Feb;19(2):86-9. doi: 02.2009/JCPSP.8689.

PMID:
19208310
6.

The role of thyroid autoantibodies in the development of thyroid dysfunction in Taiwanese chronic hepatitis C patients with interferon-alpha and ribavirin combination therapy.

Huang JF, Chuang WL, Dai CY, Chen SC, Lin ZY, Lee LP, Lee PL, Wang LY, Hsieh MY, Chang WY, Yu ML.

J Viral Hepat. 2006 Jun;13(6):396-401.

PMID:
16842442
7.

[Evolution of Sjögren syndrome associated with hepatitis C virus when chronic hepatitis C is treated by interferon or the association of interferon and ribavirin].

Doffoël-Hantz V, Loustaud-Ratti V, Ramos-Casals M, Alain S, Bezanahary H, Liozon E, Fauchais AL, Vidal E.

Rev Med Interne. 2005 Feb;26(2):88-94. French.

PMID:
15710254
8.

Correlates and prognostic value of the first-phase hepatitis C virus RNA kinetics during treatment.

Durante-Mangoni E, Zampino R, Portella G, Adinolfi LE, Utili R, Ruggiero G.

Clin Infect Dis. 2009 Aug 15;49(4):498-506. doi: 10.1086/600887.

9.

Interferon alpha and ribavirin in the treatment of children with chronic hepatitis C.

Figlerowicz M, Sluzewski W, Kowala-Piaskowska A, Mozer-Lisewska I.

Eur J Pediatr. 2004 Apr;163(4-5):265-7. Epub 2004 Feb 27. No abstract available.

PMID:
14991399
10.

Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy.

Hsu CS, Liu CH, Liu CJ, Chen CL, Lai MY, Chen PJ, Chen DS, Kao JH.

Antivir Ther. 2009;14(1):45-54.

PMID:
19320236
11.

Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection.

Alvarez-Uria G, Day JN, Nasir AJ, Russell SK, Vilar FJ.

Liver Int. 2009 Aug;29(7):1051-5. doi: 10.1111/j.1478-3231.2008.01958.x.

PMID:
19580634
12.

Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy.

Mori N, Imamura M, Kawakami Y, Saneto H, Kawaoka T, Takaki S, Aikata H, Takahashi S, Chayama K; Hiroshima Liver Study Group.

J Med Virol. 2009 Apr;81(4):640-9. doi: 10.1002/jmv.21438.

PMID:
19235866
13.

Effects of combined antiviral therapy on asymptomatic mixed cryoglobulinemia in naive patients with chronic hepatitis C virus infection: a preliminary study.

D'Amico E, Chincoli C, Cacciatore P, di Pasqua G, Cosentino L, Riario-Sforza G, Pennese E, Capani F, Palazzi C.

Dig Dis Sci. 2005 Dec;50(12):2344-7.

PMID:
16416186
14.

Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study.

Bargiggia S, Thorburn D, Anderloni A, Ardizzone S, Giorgi A, Bianchi Porro G, Parente F.

Aliment Pharmacol Ther. 2005 Aug 1;22(3):209-15.

15.

Thyroid disorders in patients with chronic hepatitis C using interferon-alpha and ribavirin therapy.

Andrade LJ, Atta AM, Atta ML, Mangabeira CN, Paraná R.

Braz J Infect Dis. 2011 Jul-Aug;15(4):377-81.

16.

Interferon-related thyroid autoimmunity and long-term clinical outcome of chronic hepatitis C.

Morisco F, Mazziotti G, Rotondi M, Tuccillo C, Iasevoli P, Del Buono A, Sorvillo F, Amato G, Marmo R, Caporaso N, Carella C.

Dig Liver Dis. 2001 Apr;33(3):247-53.

PMID:
11407670
17.

Summaries for patients. Treatment for hepatitis C virus infection among inmates.

[No authors listed]

Ann Intern Med. 2003 Feb 4;138(3):I-50. No abstract available.

PMID:
12558381
18.

Thyroid disorders during interferon alpha therapy in 625 patients with chronic hepatitis C: a prospective cohort study.

Kabbaj N, Guedira MM, El Atmani H, El Alaoui M, Mohammadi M, Benabed K, Lachkar H, Benaïssa A.

Ann Endocrinol (Paris). 2006 Sep;67(4):343-7.

PMID:
17072240
19.

Interferon-alpha therapy within the first year after acute hepatitis C infection in hemodialysis patients: efficacy and tolerance.

Rocha CM, Perez RM, Narciso JL, Ferreira AP, Lemos LB, Medina-Pestana JO, Silva AE, Ferraz ML.

Eur J Gastroenterol Hepatol. 2007 Feb;19(2):119-23.

PMID:
17272996
20.

Immunological and mutagenic actions of ribavirin monotherapy preceding combination therapy with interferon for patients with chronic hepatitis C.

Ogawa K, Hige S, Nakanishi M, Yamamoto Y, Chuma M, Nagasaka A, Asaka M.

Antivir Ther. 2009;14(4):513-22.

PMID:
19578236
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk